Organic Active Ingredients TRIZ Cases

A triacylglycerol composition with alpha-linolenic acid inhibits gastric inhibitory polypeptide secretion from intestinal K cells.

A proteolysis-targeting chimera binds tissue transglutaminase 2 and an E3 ligase to trigger protein degradation.

Regioselective oxidation converts aldehyde groups to carboxylic acids on pyrazole rings using standard reaction conditions.

Carbamate intermediates replace BOC groups to raise Linagliptin yield above 80 percent while removing regioisomer impurities.

Rapidly disintegrating tablets mask bitter amphetamine sulfate taste via particle coating, resolving pediatric swallowing difficulties and non-compliance.

Repurposed compounds inhibit viral proteins, accelerating treatment development while maintaining known safety profiles.

A phenolic-formaldehyde condensation product targets the SARS-CoV-2 main protease to reduce viral replication.

Picolinic acid targets host cellular processes to block viral entry, providing broad-spectrum activity against diverse viruses while minimizing resistance risk.

Substituted pyrazolo-pyrimidine structures optimize pharmacokinetic half-life and reduce toxicity while maintaining potent TRK inhibition.

Segmented Cav-1 peptides reduce formulation complexity while maintaining bioactivity to treat pathogen-induced lung injury.

Novel substituted cyclobutylbenzene compounds inhibit indoleamine 2,3-dioxygenase to restore suppressed T-cell activity.

Low-melting gelatin and controlled drying preserve bacterial viability during production.

Fused heteroaryl compounds address inadequate late sodium current modulation by optimizing molecular structure for selective channel targeting.

Gene-edited iPSC-derived RPE cells repair damaged retinal tissue and inhibit choroidal neovascularization.

A bispecific compound recruits the CRL4CRBN E3 ubiquitin ligase to tag target proteins.

Piperazinotriazole compounds improve metabolic stability and selectivity by modifying molecular substituents to reduce toxicity.

A lyophilized cytotoxic dipeptide preparation dissolves directly in aqueous solutions without organic solvents.

Substituted naphthyridines inhibit Syk kinase to treat inflammatory diseases while managing molecular complexity.

N-cyanopyrrolidine compounds inhibit the deubiquitylating enzyme USP30 to enhance mitophagy and reduce oxidative stress in mitochondrial dysfunction.

Novel transposon systems integrate heterologous DNA into eukaryotic genomes using optimized transposase enzymes.

Guanosine formulations replenish depleted host nucleotide pools to prevent post-viral neurological and clotting disorders.

PLGA-g-PEI particles enhance transfection efficiency while reducing cytotoxicity in neural cells.

Antisense oligonucleotides target natural antisense transcripts to resolve incomplete gene expression modulation and up-regulate MBTPS1.

Alpha-halogen-substituted thiophene compounds act as potent LPA receptor antagonists to treat non-alcoholic steatohepatitis and related diseases.

Polymorphic forms of Icotinib exhibit distinct crystal structures that improve dissolution rates while enhancing chemical stability for cancer treatment.

Cyanoquinoline derivatives overcome drug resistance in metastatic cancer by inhibiting receptor tyrosine kinase activity.

Compounds inhibit Memapsin 1 to reduce beta-amyloid accumulation, addressing limited treatment options.

A chitosan oligomer and zinc oxide nanoparticle formulation targets multidrug-resistant bacteria through synergistic membrane disruption.

Flaky anlotinib dihydrochloride crystals achieve rapid dissolution while maintaining mixing homogeneity despite cohesiveness challenges.

Azetidine derivative compounds modulate Janus kinase activity through tailored molecular structures.

Tramadol-celecoxib co-crystals improve solubility and stability to address opioid side effects.

Formula I compounds inhibit wild-type and mutant kinases like Bcr-Abl(T315I) to overcome resistance mutations in leukemia treatment.

Genipin crosslinks fibrin within the thrombus to prevent compaction and reduce recurrence risk.

Crosslinked muco-adhesive polymers entrap lipid nanoparticles, maintaining stability under shear flow while enabling controlled drug release.

Pyrrolo[2,1-f][1,2,4]triazine derivatives resolve synthesis complexity and activity limitations in cancer treatment by inhibiting the PI3K pathway.

A ketogenic diet induces ketogenesis while ketamine provides NMDA receptor antagonism to address metabolic and neurobehavioral aspects of eating disorders.

Compounds inhibit Mps1 kinase activity to disrupt spindle checkpoint function, addressing the lack of effective targeting in current anticancer therapies.

4-(Azacycloalkyl)-benzene-1,3-diol derivatives block melanogenesis via potent tyrosinase inhibition while minimizing cytotoxicity to melanocytes.

Synthetic carbohydrate-based tripod amphiphiles solubilize membrane proteins by forming small micelles that preserve native structure.

Small molecule inhibitors target the bromodomain of SP140 protein to modulate gene expression.

Oligopyrrolamide compounds modulate amyloidogenic peptide structure to inhibit oligomerization.

Combines FGFR4 inhibitor with senolytic drug to inhibit signaling and eliminate senescent cells in pancreatic cancer.

2-Oxoindole derivatives resolve the lack of clinical agents by targeting 14-3-3 proteins, achieving antitumor activity without toxicity to healthy cells.

Dry mixing micronized melatonin with microcrystalline cellulose achieves uniform content distribution without organic solvents.

Deuterium substitution enhances metabolic stability and bioavailability of quinolone inhibitors targeting the BCL6 BTB domain.

Arylamino compounds degrade estrogen receptors to treat breast cancer while preventing endometrial hyperplasia.

Concerted elimination bypasses hazardous free acid intermediates to improve yield and safety.